Compound Evidence File
#EC-2026-0571
17a-Methyl-1-Testosterone
Filed under Oral Tablets. The bureau holds 165 laboratory returns for this compound from 53 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
53 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 7 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| HomopeptideCASE #VI-2026-0760 | A | 4 | 10.0 | 9.9 | 10.0 | 21 May 2026 | 21 May 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 4 | 10.0 | 9.9 | 10.0 | 20 Apr 2026 | 9 Jul 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 3 | 10.0 | 9.9 | 10.0 | 5 May 2026 | 5 Jul 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 3 | 10.0 | 9.9 | 10.0 | 27 Dec 2025 | 25 Mar 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 3 | 10.0 | 9.9 | 10.0 | 26 Apr 2026 | 19 Jun 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 3 | 10.0 | 10.0 | 10.0 | 7 Dec 2025 | 2 May 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 3 | 10.0 | 9.9 | 10.0 | 16 May 2026 | 6 Jun 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 3 | 10.0 | 9.9 | 10.0 | 24 Dec 2025 | 1 Jun 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 3 | 10.0 | 9.9 | 10.0 | 10 Feb 2026 | 27 Jul 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 3 | 10.0 | 10.0 | 10.0 | 7 Apr 2026 | 15 Aug 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 2 | 10.0 | 10.0 | 10.0 | 4 Mar 2026 | 7 Mar 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 4 | 9.9 | 9.9 | 10.0 | 26 Jan 2026 | 8 Jul 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 4 | 9.9 | 9.9 | 10.0 | 23 Jun 2026 | 1 Aug 2026 |
| AsymchemCASE #VI-2026-0091 | A | 4 | 9.9 | 9.9 | 10.0 | 26 May 2026 | 22 Jul 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 4 | 9.9 | 9.9 | 9.9 | 26 Dec 2025 | 23 Jul 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 3 | 9.9 | 9.9 | 9.9 | 8 Jan 2026 | 7 Jun 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 3 | 9.9 | 9.9 | 10.0 | 28 Jan 2026 | 28 Jun 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 3 | 9.9 | 9.9 | 10.0 | 8 Jan 2026 | 8 Jul 2026 |
| SinoPepCASE #VI-2026-0387 | A | 3 | 9.9 | 9.9 | 9.9 | 27 Feb 2026 | 8 Jul 2026 |
| BachemCASE #VI-2026-0314 | A | 2 | 9.9 | 9.9 | 10.0 | 20 Apr 2026 | 21 Jun 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 2 | 9.9 | 9.9 | 10.0 | 3 May 2026 | 3 Jun 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 2 | 9.9 | 9.9 | 10.0 | 5 Jul 2026 | 14 Aug 2026 |
| OmegAminoCASE #VI-2026-0014 | X | 1 | 9.5 | 9.5 | 9.5 | 28 Mar 2025 | 28 Mar 2025 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 4 | 8.7 | 8.2 | 9.2 | 25 May 2026 | 25 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 7 | 8.5 | 7.5 | 9.0 | 24 May 2026 | 24 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 7 | 8.5 | 7.6 | 10.0 | 24 May 2026 | 24 May 2026 |
| Trusted PeptideCASE #VI-2026-0499 | X | 1 | 8.4 | 8.4 | 8.4 | 9 Jun 2025 | 9 Jun 2025 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 8 | 8.3 | 6.5 | 9.7 | 24 May 2026 | 24 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 2 | 8.2 | 8.1 | 8.3 | 21 May 2026 | 21 May 2026 |
| Zenith Jove Peptide ZJCASE #VI-2026-0570 | X | 1 | 7.6 | 7.6 | 7.6 | 7 May 2025 | 7 May 2025 |
| Peptide-SCASE #VI-2026-0111 | X | 4 | 7.4 | 5.2 | 9.3 | 8 Jul 2025 | 23 May 2026 |
| Paramount PeptidesCASE #VI-2026-0550 | X | 6 | 7.2 | 4.3 | 9.4 | 3 Jun 2025 | 23 May 2026 |
| ScienceCASE #VI-2026-0636 | X | 1 | 7.1 | 7.1 | 7.1 | 16 Mar 2025 | 16 Mar 2025 |
| Platinum CryoCASE #VI-2026-0406 | X | 1 | 6.9 | 6.9 | 6.9 | 11 Jun 2025 | 11 Jun 2025 |
| Zen PeptidesCASE #VI-2026-0940 | X | 1 | 6.9 | 6.9 | 6.9 | 13 Feb 2025 | 13 Feb 2025 |
| Qing Li PeptideCASE #VI-2026-0469 | X | 15 | 6.8 | 4.6 | 8.6 | 17 Dec 2024 | 17 May 2026 |
| Peptide TechnologiesCASE #VI-2026-0694 | X | 1 | 6.6 | 6.6 | 6.6 | 2 Apr 2025 | 2 Apr 2025 |
| NexaphCASE #VI-2026-0944 | X | 13 | 6.5 | 4.3 | 9.4 | 27 Feb 2025 | 24 May 2026 |
| Limitless Life NootropicsCASE #VI-2026-0980 | X | 2 | 6.5 | 6.1 | 7.0 | 21 May 2025 | 21 May 2026 |
| Shanghai JinBei Chemical TechnologyCASE #VI-2026-0107 | X | 1 | 6.4 | 6.4 | 6.4 | 25 Apr 2025 | 25 Apr 2025 |
| Coastal PeptidesCASE #VI-2026-0958 | X | 1 | 6.2 | 6.2 | 6.2 | 3 Jul 2025 | 3 Jul 2025 |
| Swiss ChemsCASE #VI-2026-0030 | X | 1 | 5.7 | 5.7 | 5.7 | 24 Apr 2025 | 24 Apr 2025 |
| UWA Elite PeptidesCASE #VI-2026-0130 | X | 1 | 5.7 | 5.7 | 5.7 | 3 Jul 2025 | 3 Jul 2025 |
| Shandong Aishi BiotechnologyCASE #VI-2026-0308 | X | 1 | 5.5 | 5.5 | 5.5 | 3 Jul 2025 | 3 Jul 2025 |
| Forever Young PharmacyCASE #VI-2026-0654 | X | 2 | 5.2 | 4.7 | 5.6 | 8 Jul 2025 | 25 May 2026 |
| DeuschemCASE #VI-2026-0004 | X | 2 | 5.2 | 3.9 | 6.6 | 20 Jun 2025 | 21 May 2026 |
| YB PeptideCASE #VI-2026-0813 | X | 1 | 5.1 | 5.1 | 5.1 | 25 Apr 2025 | 25 Apr 2025 |
| NextGen HealthCASE #VI-2026-0604 | X | 1 | 4.9 | 4.9 | 4.9 | 7 May 2025 | 7 May 2025 |
| Hebei Chengtong TechnologyCASE #VI-2026-0520 | X | 1 | 1.9 | 1.9 | 1.9 | 28 Mar 2025 | 28 Mar 2025 |
| Oasis PeptidesCASE #VI-2026-0404 | X | 1 | 1.8 | 1.8 | 1.8 | 14 Jan 2025 | 14 Jan 2025 |
| Explicit SarmsCASE #VI-2026-0017 | X | 1 | 0.0 | 0.0 | 0.0 | 24 Apr 2025 | 24 Apr 2025 |
| Lejian Biotech PeptideCASE #VI-2026-0746 | X | 1 | 0.0 | 0.0 | 0.0 | 17 Dec 2024 | 17 Dec 2024 |
Open any subject to view the batch-level evidence for 17a-Methyl-1-Testosterone alone.